ENLV Stock Summary and Trading Ideas (Enlivex Ltd. - | NASDAQ:ENLV)

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Enlivex Ltd. - trades on the NASDAQ stock market under the symbol ENLV.

As of April 2, 2026, ENLV stock price declined to $0.95 with 303,518 million shares trading.

ENLV has a beta of 0.65, meaning it tends to be less sensitive to market movements. ENLV has a correlation of 0.01 to the broad based SPY ETF.

ENLV has a market cap of $227.83 million. This is considered a Small Cap stock.

In the last 3 years, ENLV traded as high as $4.59 and as low as $.66.

The top ETF exchange traded funds that ENLV belongs to (by Net Assets): QQQS.

ENLV has underperformed the market in the last year with a price return of -5.7% while the SPY ETF gained +17.5%. However, in the short term, ENLV had mixed performance relative to the market. It has outperformed in the last 3 months, returning +26.1% vs -3.7% return in SPY. But in the last 2 weeks, ENLV shares have been beat by the market, returning -11.9% compared to an SPY return of -0.1%.

ENLV support price is $.91 and resistance is $1.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENLV shares will trade within this expected range on the day.